Letter to editor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Letter to editor

Published:2022-05-17 Issue: Volume:7 Page:58-60
ISSN:2456-3994
Container-title:International Journal of Molecular and Immuno Oncology
language:en
Short-container-title:IJMIO

Author:

Purvish M Parikh¹,Mehta Prashant²,Patel Amol³

Affiliation:

1. Department of Clinical Hematology, MGMCH, Jaipur, Rajasthan, India,

2. Department of Medical Oncology and BMT, Asian Institute of Medical Sciences, Faridabad, Haryana, India,

3. Department of Medical Oncology, INHS Asvini, Mumbai, Maharashtra, India,

Publisher

Scientific Scholar

Subject

General Medicine

Reference6 articles.

1. Outcome in patients of hormone receptor (HR) positive Her 2 negative metastatic breast cancer treated with palbociclib a real-world experience;Bapna;Ind J Mol Immunol Oncol,2021

2. Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor-positive breast cancer patients;Attuluri;BMC Cancer,2019

3. Cost-effectiveness analysis of adding palbociclib as a second-line endocrine therapy for HR+/HER2-metastatic breast cancer from the US and Chinese perspectives;Zhang;Clin Ther,2019

4. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: A health economic analysis of the Swiss group for clinical cancer research (SAKK);Matter-Walstra;Breast Cancer Res Treat,2016

5. Palbociclib in hormone-receptor-positive advanced breast cancer: A cost-utility analysis;Raphael;Eur J Cancer,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP